Calcific Uremic Arteriolopathy: Contemporary Pharmacotherapy

Advances in Chronic Kidney Disease

Volumn 17, Issue 5, 2010, Pages 428-438

  Mason, Darius ^a,b   Best, Sara D ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Calcific uremic arteriolopathy; Calciphylaxis; Cinacalcet; Sodium thiosulfate

Indexed keywords

ALBUMIN; CALCIUM PHOSPHATE; CINACALCET; CORTICOSTEROID; ERYTHROPOIETIN; ETIDRONIC ACID; IBANDRONIC ACID; IRON DEXTRAN; PAMIDRONIC ACID; PARATHYROID HORMONE; SODIUM THIOSULFATE; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN D DERIVATIVE; WARFARIN;

ALBUMIN BLOOD LEVEL; ARTERY CALCIFICATION; BREAST CALCIFICATION; CALCIFIC UREMIC ARTERIOLOPATHY; CALCINOSIS; CAUCASIAN; CLINICAL FEATURE; DEBRIDEMENT; DIABETES MELLITUS; DIALYSIS; DRUG FEVER; DRUG MEGADOSE; FEMALE; GANGRENE; HEADACHE; HUMAN; HYPERBARIC OXYGEN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INJECTION SITE PAIN; JAW OSTEONECROSIS; LIVEDO RETICULARIS; LOW DRUG DOSE; MAGGOT THERAPY; MALNUTRITION; METABOLIC ACIDOSIS; NAUSEA; OBESITY; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PENILE NECROSIS; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SOFT TISSUE CALCIFICATION; STATISTICAL SIGNIFICANCE; TONGUE DISEASE; TRANSCUTANEOUS OXYGEN MONITORING; VOMITING;

EID: 77955805227     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.05.006     Document Type: Review

References (70)

1. Angelis M., Wong L.L., Myers S.A., et al. Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery 1997, 122:1083-1089. discussion 1089-1090.
2. Rogers N.M., Coates P.T. Calcific uraemic arteriolopathy: An update. Curr Opin Nephrol Hypertens 2008, 17:629-634.
3. Nigwekar S.U., Wolf M., Sterns R.H., et al. Calciphylaxis from nonuremic causes: A systematic review. Clin J Am Soc Nephrol 2008, 3:1139-1143.
4. Alikadic N., Kovac D., Krasna M., et al. Review of calciphylaxis and treatment of a severe case after kidney transplantation with iloprost in combination with hyperbaric oxygen and cultured autologous fibrin-based skin substitutes. Clin Transplant 2009, 23:968-974.
5. Raymond C.B., Wazny L.D. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm 2008, 65:1419-1429.
6. Naik B.J., Lynch D.J., Slavcheva E.G., et al. Calciphylaxis: Medical and surgical management of chronic extensive wounds in a renal dialysis population. Plast Reconstr Surg 2004, 113:304-312.
7. Bahar G., Mimouni D., Feinmesser M., et al. Subtotal parathyroidectomy: A possible treatment for calciphylaxis. Ear Nose Throat J 2003, 82:390-393.
8. Fine A., Zacharias J. Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 2002, 61:2210-2217.
9. Mureebe L., Moy M., Balfour E., et al. Calciphylaxis: A poor prognostic indicator for limb salvage. J Vasc Surg 2001, 33:1275-1279.
10. Weenig R.H., Sewell L.D., Davis M.D., et al. Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007, 56:569-579.
11. Han M.M., Pang J., Shinkai K., et al. Calciphylaxis and bone scintigraphy: Case report with histological confirmation and review of the literature. Ann Nucl Med 2007, 21:235-238.
12. Cosmin A., Soudry G. A case of severe calciphylaxis seen on three-phase bone scan. Clin Nucl Med 2005, 30:765-766.
13. Wilmer W.A., Voroshilova O., Singh I., et al. Transcutaneous oxygen tension in patients with calciphylaxis. Am J Kidney Dis 2001, 37:797-806.
14. Ahmed S., O'Neill K.D., Hood A.F., et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001, 37:1267-1276.
15. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol 2004, 15:2959-2964.
16. Schoppet M., Shroff R.C., Hofbauer L.C., et al. Exploring the biology of vascular calcification in chronic kidney disease: What's circulating?. Kidney Int 2008, 73:384-390.
17. Weenig R.H. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008, 58:458-471.
18. Rogers N.M., Teubner D.J., Coates P.T. Calcific uremic arteriolopathy: Advances in pathogenesis and treatment. Semin Dial 2007, 20:150-157.
19. Mazhar A.R., Johnson R.J., Gillen D., et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001, 60:324-332.
20. Koos R., Krueger T., Westenfeld R., et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009, 101:706-713.
21. Lee P., Sevastos J., Campbell L.V. Surviving calciphylaxis. J Bone Miner Metab 2009, 27:247-250.
22. Tittelbach J., Graefe T., Wollina U. Painful ulcers in calciphylaxis-combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat 2001, 12:211-214.
23. Podymow T., Wherrett C., Burns K.D. Hyperbaric oxygen in the treatment of calciphylaxis: A case series. Nephrol Dial Transplant 2001, 16:2176-2180.
24. Rogers N.M., Coates P.T. Calcific uremic arteriolopathy-the argument for hyperbaric oxygen and sodium thiosulfate. Semin Dial 2010, 23:38-42.
25. Banky J.P., Dowling J.P., Miles C. Idiopathic calciphylaxis. Australas J Dermatol 2002, 43:190-193.
26. Basile C., Montanaro A., Masi M., et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: A case series. J Nephrol 2002, 15:676-680.
27. Dean S.M., Werman H. Calciphylaxis: A favorable outcome with hyperbaric oxygen. Vasc Med 1998, 3:115-120.
28. Dwyer K.M., Francis D.M., Hill P.A., et al. Calcific uraemic arteriolopathy: Local treatment and hyperbaric oxygen therapy. Nephrol Dial Transplant 2002, 17:1148-1149.
29. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(suppl 3):S1-S201.
30. Girotto J.A., Harmon J.W., Ratner L.E., et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001, 130:645-650. discussion 650-641.
31. Robinson M.R., Augustine J.J., Korman N.J. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol 2007, 143:152-154.
32. Fine A., Fontaine B. Calciphylaxis: The beginning of the end?. Perit Dial Int 2008, 28:268-270.
33. Hayden M.R., Tyagi S.C., Kolb L., et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: The emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005, 4:4.
34. Cicone J.S., Petronis J.B., Embert C.D., et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004, 43:1104-1108.
35. Brucculeri M., Cheigh J., Bauer G., et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005, 18:431-434.
36. Guerra G., Shah R.C., Ross E.A. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: Case report. Nephrol Dial Transplant 2005, 20:1260-1262.
37. Norris B., Vaysman V., Line B.R. Bone scintigraphy of calciphylaxis: A syndrome of vascular calcification and skin necrosis. Clin Nucl Med 2005, 30:725-727.
38. Tokashiki K., Ishida A., Kouchi M., et al. Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient. Clin Nephrol 2006, 66:140-143.
39. Mataic D., Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail 2006, 28:361-363.
40. Meissner M., Gille J., Kaufmann R. Calciphylaxis: No therapeutic concepts for a poorly understood syndrome?. J Dtsch Dermatol Ges 2006, 4:1037-1044.
41. Thang O.H., Jaspars E.H., ter Wee P.M. Necrotizing mastitis caused by calciphylaxis. Nephrol Dial Transplant 2006, 21:2020-2021.
42. Araya C.E., Fennell R.S., Neiberger R.E., et al. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006, 1:1161-1166.
43. Ackermann F., Levy A., Daugas E., et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 2007, 143:1336-1337. author reply 1338.
44. Baker B.L., Fitzgibbons C.A., Buescher L.S. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol 2007, 143:269-270.
45. Kyritsis I., Gombou A., Griveas I., et al. Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. Int J Artif Organs 2008, 31:742-744.
46. Hackett B.C., McAleer M.A., Sheehan G., et al. Calciphylaxis in a patient with normal renal function: Response to treatment with sodium thiosulfate. Clin Exp Dermatol 2009, 34:39-42.
47. Soni S., Leslie W.D. Bone scan findings in metastatic calcification from calciphylaxis. Clin Nucl Med 2008, 33:502-504.
48. Subramaniam K., Wallace H., Sinniah R., et al. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. Australas J Dermatol 2008, 49:30-34.
49. Musso C.G., Enz P., Vidal F., et al. Use of sodium thiosulfate in the treatment of calciphylaxis. Saudi J Kidney Dis Transpl 2009, 20:1065-1068.
50. Kalisiak M., Courtney M., Lin A., et al. Calcific uremic arteriolopathy (calciphylaxis): Successful treatment with sodium thiosulfate in spite of elevated serum phosphate. J Cutan Med Surg 2009, 13(suppl 1):S29-S34.
51. Schlieper G., Brandenburg V., Ketteler M., et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009, 5:539-543.
52. Adirekkiat S., Sumethkul V., Ingsathit A., et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:1923-1929.
53. Hanafusa T., Yamaguchi Y., Tani M., et al. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007, 57:1021-1025.
54. da Costa J.B., da Costa A.G., Gomes M.M. Pamidronate as a treatment option in calciphylaxis. J Eur Acad Dermatol Venereol 2008, 22:1128-1130.
55. Leon L.R. Treating distal calciphylaxis with therapy associated with sevelamer and bisphosphonates. Nefrologia 2009, 29:92-93.
56. Monney P., Nguyen Q.V., Perroud H., et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004, 19:2130-2132.
57. Shiraishi N., Kitamura K., Miyoshi T., et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006, 48:151-154.
58. Schliep S., Schuler G., Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol 2008, 18:554-556.
59. Almafragi A., Vandorpe J., Dujardin K. Calciphylaxis in a cardiac patient without renal disease. Acta Cardiol 2009, 64:91-93.
60. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
61. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20:2105-2115.
62. Arenas M.D., Gil M.T., Gutierrez M.D., et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol 2008, 70:261-264.
63. Mohammed I.A., Sekar V., Bubtana A.J., et al. Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 2008, 23:387-389.
64. Pallure V., Comte C., Leray-Mouragues H., et al. Cinacalcet as first-line treatment for calciphylaxis. Acta Derm Venereol 2008, 88:62-63.
65. Prey S., Sparsa A., Durox H., et al. Calciphylaxis treated by cinacalcet: A medical alternative to parathyroidectomy. Rev Med Interne 2009, 30:186-189.
66. Sharma A., Burkitt-Wright E., Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 2006, 155:1295-1297.
67. Velasco N., MacGregor M.S., Innes A., et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy?. Nephrol Dial Transplant 2006, 21:1999-2004.
68. Sewell L.D., Weenig R.H., Davis M.D., et al. Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol 2004, 140:1045-1048.
69. KDIGO Clinical Practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 76:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
70. Cardus A., Panizo S., Parisi E., et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007, 22:860-866.